pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,079 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT812Endpoints613BioPharma Dive235onclive165Fierce Biotech81BioSpace79raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
← prev
page 28 of 44
next →
21
fda recalls20
fda medwatch16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 1mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 1mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 1mo ago↗ source
  • Akeso, Summit drug extends survival in closely watched lung cancer trial
    Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
    BioPharma Dive · 1mo ago↗ source
  • ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
    Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 1mo ago↗ source
  • STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
    Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
    STAT · 2mo ago↗ source
  • STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
    STAT · 2mo ago↗ source
  • STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
    Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
    STAT · 2mo ago↗ source
  • STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
    You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
    STAT · 2mo ago↗ source
  • At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
    Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
    BioPharma Dive · 2mo ago↗ source
  • Bristol Myers unveils data for one of its next-gen blood cancer drugs
    Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchers
    The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.
    STAT · 2mo ago↗ source
  • Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
    A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
    BioPharma Dive · 2mo ago↗ source
  • Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
    A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
    STAT · 2mo ago↗ source
  • Allogene CEO to step down; Agios drug fails key test
    David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
    BioPharma Dive · 2mo ago↗ source
  • Can a chaotic FDA still deliver on faster drug development?
    As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep speedier drug approvals on track.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
    Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
    STAT · 2mo ago↗ source
  • STAT+: Allogene CEO David Chang stepping down
    Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
    STAT · 2mo ago↗ source
  • STAT+: Massachusetts sues UnitedHealth, alleging fraud in state’s Medicaid plans for seniors
    State AG alleges UnitedHealthcare claimed some members were sicker to boost its profits.
    STAT · 2mo ago↗ source
  • Which vaccines will curb the Ebola outbreak? WHO debates
    The growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Rounds
    STAT · 2mo ago↗ source